ChengDa Pharmaceuticals Co., Ltd.

XSEC:301201 Stock Report

Market Cap: CN¥3.2b

ChengDa Pharmaceuticals Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Gang Lu

Chief executive officer

CN¥892.7k

Total compensation

CEO salary percentagen/a
CEO tenure9.8yrs
CEO ownershipn/a
Management average tenure7.4yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO

Gang Lu (49 yo)

9.8yrs

Tenure

CN¥892,700

Compensation

Mr. Gang Lu serves as GM & Director of ChengDa Pharmaceuticals Co., Ltd. since March 31, 2015.

Leadership Team

NamePositionTenureCompensationOwnership
Gang Lu
GM & Director9.8yrsCN¥892.70kno data
Honglin Huang
Deputy GM & Director15yrsCN¥553.20k12.89%
CN¥ 411.7m
Jin Lu
Deputy GM & Directorno dataCN¥613.20kno data
Xiaojing Yang
Deputy GM & Secretary5yrsCN¥413.70kno data
Yu Feng
Deputy General Manager5yrsCN¥884.10kno data

7.4yrs

Average Tenure

46yo

Average Age

Experienced Management: 301201's management team is seasoned and experienced (7.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gang Lu
GM & Director9.8yrsCN¥892.70kno data
Honglin Huang
Deputy GM & Director15yrsCN¥553.20k12.89%
CN¥ 411.7m
Jin Lu
Deputy GM & Director1.6yrsCN¥613.20kno data
Yi Yu
Independent Director5.2yrsCN¥72.00kno data
Ping Wang
Independent Director5.1yrsCN¥72.00kno data
Jianli Ge
Chairman of the Board15yrsCN¥976.90k27.75%
CN¥ 886.0m
Sunliang Cui
Independent Director5.1yrsCN¥72.00kno data

5.2yrs

Average Tenure

59yo

Average Age

Experienced Board: 301201's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 23:33
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChengDa Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution